Table 3 Lipid profile changes in the ITT population.
Lipid parameter | Â | Rosiglitazone | Placebo |
|---|---|---|---|
(mmol/L) | Â | (N = 25) | (N = 29) |
Total Cholesterol | Â | Â | Â |
Baseline | geometric mean | 4.14 | 4.36 |
| Â | (-SE, +SE) | 3.97, 4.33 | 4.15, 4.58 |
End of treatment | geometric mean | 4.13 | 4.17 |
| Â | (-SE, +SE) | 3.97, 4.29 | 3.97, 4.37 |
% Change | geometric mean | -0.5 | -4.5 |
| Â | (-SE, +SE) | -3.24, 2.40 | -8.00, -0.85 |
P value | Â | 0.42 | Â |
HDLc | Â | Â | Â |
Baseline | geometric mean | 1.10 | 1.14 |
| Â | (-SE, +SE) | 1.04, 1.15 | 1.06, 1.22 |
End of treatment | geometric mean | 1.16 | 1.22 |
| Â | (-SE, +SE) | 1.09, 1.22 | 1.15, 1.29 |
% Change | geometric mean | 5.4 | 7.2 |
| Â | (-SE, +SE) | 1.41, 9.55 | 3.35, 11.1 |
P value | Â | 0.97 | Â |
LDLc | Â | Â | Â |
Baseline | geometric mean | 2.22 | 2.31 |
| Â | (-SE, +SE) | 2.07, 2.37 | 2.16, 2.47 |
End of treatment | geometric mean | 2.23 | 2.13 |
| Â | (-SE, +SE) | 2.10, 2.36 | 1.98, 2.28 |
% Change | geometric mean | 0.4 | -7.9 |
| Â | (-SE, +SE) | -4.07, 5.10 | -12.7, -2.82 |
P value | Â | 0.24 | Â |
Triglycerides | Â | Â | Â |
Baseline | geometric mean | 1.61 | 1.67 |
| Â | (-SE, +SE) | 1.50, 1.72 | 1.52, 1.84 |
End of treatment | geometric mean | 1.35 | 1.48 |
| Â | (-SE, +SE) | 1.24, 1.47 | 1.36, 1.61 |
% Change | geometric mean | -16.0 | -11.6 |
| Â | (-SE, +SE) | -22.4, -9.13 | -18.1, -4.65 |
P value | Â | 0.70 | Â |
Free fatty acids | Â | Â | Â |
Baseline | geometric mean | 0.58 | 0.56 |
| Â | (-SE, +SE) | 0.55, 0.62 | 0.53, 0.59 |
End of treatment | geometric mean | 0.46 | 0.60 |
| Â | (-SE, +SE) | 0.42, 0.50 | 0.57, 0.64 |
% Change | geometric mean | -20.7 | 7.8 |
| Â | (-SE, +SE) | -28.00, -12.6 | 2.86, 12.9 |
P value | Â | 0.0050 | Â |